[18f]naf Biokoσμοσ

Sodium Fluoride (18F) is a radiopharmaceutical used in PET imaging for bone scans. This EU-sourced tracer highlights areas of bone metabolism for diagnostic purposes. Commonly used to detect fractures, infections, or cancer metastases. Short half-life ensures rapid clearance for patient safety.

Sodium Fluoride (18F) is primarily used in positron emission tomography (PET) scans to evaluate bone metabolism. It helps identify abnormalities such as fractures, bone infections, or metastatic bone disease. This radiotracer is particularly useful in oncology for detecting cancer spread to bones. It may also assist in assessing joint or prosthetic complications.

After intravenous administration, Sodium Fluoride (18F) distributes rapidly to bones, highlighting areas of high metabolic activity. The tracer emits positrons that are detected by PET scanners, creating detailed images of skeletal structures. Patients typically experience no immediate physical effects, as the compound is designed for diagnostic imaging rather than therapeutic action.

Sodium Fluoride (18F) should only be handled by trained medical professionals in controlled settings. Pregnant or breastfeeding individuals should avoid exposure due to potential radiation risks. Patients with known allergies to fluoride compounds should inform their healthcare provider. Hydration before and after administration may help facilitate tracer clearance.

No significant drug interactions are reported with Sodium Fluoride (18F), as it is not metabolized by the liver. However, recent use of other radiopharmaceuticals may interfere with imaging results. Patients should disclose all medications, including supplements, to their healthcare provider. Alcohol consumption is not known to interact but may be restricted per facility protocols.